These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31196754)

  • 41. Response of gut microbiota and inflammatory status to bitter melon (Momordica charantia L.) in high fat diet induced obese rats.
    Bai J; Zhu Y; Dong Y
    J Ethnopharmacol; 2016 Dec; 194():717-726. PubMed ID: 27751827
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bioactives of
    Xu B; Li Z; Zeng T; Zhan J; Wang S; Ho CT; Li S
    Molecules; 2022 Mar; 27(7):. PubMed ID: 35408574
    [No Abstract]   [Full Text] [Related]  

  • 43. Bitter melon (Momordica charantia) attenuates atherosclerosis in apo-E knock-out mice possibly through reducing triglyceride and anti-inflammation.
    Zeng Y; Guan M; Li C; Xu L; Zheng Z; Li J; Xue Y
    Lipids Health Dis; 2018 Nov; 17(1):251. PubMed ID: 30400958
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Momordica charantia extracts ameliorate insulin resistance by regulating the expression of SOCS-3 and JNK in type 2 diabetes mellitus rats.
    Ma C; Yu H; Xiao Y; Wang H
    Pharm Biol; 2017 Dec; 55(1):2170-2177. PubMed ID: 29110587
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bitter Melon Extract Yields Multiple Effects on Intestinal Epithelial Cells and Likely Contributes to Anti-diabetic Functions.
    Chang CI; Cheng SY; Nurlatifah AO; Sung WW; Tu JH; Lee LL; Cheng HL
    Int J Med Sci; 2021; 18(8):1848-1856. PubMed ID: 33746602
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potential use of bitter melon (Momordica charantia) derived compounds as antidiabetics: In silico and in vivo studies.
    Elekofehinti OO; Ariyo EO; Akinjiyan MO; Olayeriju OS; Lawal AO; Adanlawo IG; Rocha JBT
    Pathophysiology; 2018 Dec; 25(4):327-333. PubMed ID: 29764719
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New insights into the bioactive polysaccharides, proteins, and triterpenoids isolated from bitter melon (Momordica charantia) and their relevance for nutraceutical and food application: A review.
    Bora AFM; Kouame KJE; Li X; Liu L; Pan Y
    Int J Biol Macromol; 2023 Mar; 231():123173. PubMed ID: 36642359
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Momordica charantia extract, a herbal remedy for type 2 diabetes, contains a specific 11β-hydroxysteroid dehydrogenase type 1 inhibitor.
    Blum A; Loerz C; Martin HJ; Staab-Weijnitz CA; Maser E
    J Steroid Biochem Mol Biol; 2012 Jan; 128(1-2):51-5. PubMed ID: 22001161
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ribosome-Inactivating Protein α-Momorcharin Derived from Edible Plant
    Chen YJ; Zhu JQ; Fu XQ; Su T; Li T; Guo H; Zhu PL; Lee SK; Yu H; Tse AK; Yu ZL
    Toxins (Basel); 2019 Nov; 11(12):. PubMed ID: 31779275
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of antidiabetic effects of saponins and polysaccharides from Momordica charantia L. in STZ-induced type 2 diabetic mice.
    Wang Q; Wu X; Shi F; Liu Y
    Biomed Pharmacother; 2019 Jan; 109():744-750. PubMed ID: 30551527
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Polysaccharide from fermented Momordica charantia L. with Lactobacillus plantarum NCU116 ameliorates type 2 diabetes in rats.
    Gao H; Wen JJ; Hu JL; Nie QX; Chen HH; Xiong T; Nie SP; Xie MY
    Carbohydr Polym; 2018 Dec; 201():624-633. PubMed ID: 30241862
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of Momordica charantia (Bitter Melon) on Ischemic Diabetic Myocardium.
    Czompa A; Gyongyosi A; Szoke K; Bak I; Csepanyi E; Haines DD; Tosaki A; Lekli I
    Molecules; 2017 Mar; 22(3):. PubMed ID: 28335529
    [No Abstract]   [Full Text] [Related]  

  • 53. Bitter gourd (Momordica charantia) is a cornucopia of health: a review of its credited antidiabetic, anti-HIV, and antitumor properties.
    Fang EF; Ng TB
    Curr Mol Med; 2011 Jul; 11(5):417-36. PubMed ID: 21568930
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structure determination, bitterness evaluation and hepatic gluconeogenesis inhibitory activity of triterpenoids from the Momordica charantia fruit.
    Deng Y; Ma Y; Liu H; Zhang Y; Wei Z; Liu G; Tang X; Jia X
    Food Chem; 2022 Mar; 372():131224. PubMed ID: 34624787
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Susceptibility of poultry associated bacterial pathogens to Momordica charantia fruits and evaluation of in vitro biological properties.
    Lydia D E; Gupta C; Khusro A; Salem AZM
    Microb Pathog; 2019 Jul; 132():222-229. PubMed ID: 31059755
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    Peeran SW; Murugan M; Fageeh H; Ibrahim W; Al-Ak'hali MS; Basheer SN; Mohamed AMB
    J Pharm Bioallied Sci; 2024 Apr; 16(Suppl 2):S1554-S1564. PubMed ID: 38882883
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats.
    Shih CC; Lin CH; Lin WL; Wu JB
    J Ethnopharmacol; 2009 May; 123(1):82-90. PubMed ID: 19429344
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antiglycation and Antioxidant Properties of Momordica charantia.
    Aljohi A; Matou-Nasri S; Ahmed N
    PLoS One; 2016; 11(8):e0159985. PubMed ID: 27513747
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Extraction, quantification, and antioxidant activities of phenolics from pericarp and seeds of bitter melons (Momordica charantia) harvested at three maturity stages (immature, mature, and ripe).
    Horax R; Hettiarachchy N; Chen P
    J Agric Food Chem; 2010 Apr; 58(7):4428-33. PubMed ID: 20225855
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NMR-based metabolomic profiling of the differential concentration of phytomedicinal compounds in pericarp, skin and seeds of
    Mishra S; Ankit ; Sharma R; Gogna N; Dorai K
    Nat Prod Res; 2022 Jan; 36(1):390-395. PubMed ID: 33438465
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.